Literature DB >> 27421609

Decreased hippocampal metabolism in high-amyloid mild cognitive impairment.

Bernard J Hanseeuw1, Aaron P Schultz2, Rebecca A Betensky3, Reisa A Sperling2, Keith A Johnson2.   

Abstract

INTRODUCTION: Hippocampal volume (HV), cortical metabolism, and thickness are decreased in mild cognitive impairment (MCI). Hippocampal metabolism (HM) studies comparing MCI and clinically normal (CN) elderly gave inconsistent results. As hippocampus is a key region in Alzheimer's disease, we hypothesized that HM is specifically decreased in high-amyloid MCI.
METHODS: Overall, 250 CN and 45 MCI underwent three-dimensional magnetic resonance imaging, fludeoxyglucose-positron emission tomography, and fluorodeoxyglucose-positron emission tomography (PET), and Pittsburgh Compound B (PiB) PET. We investigated the interaction between clinical and amyloid status on HM, HV, cortical metabolism, and thickness using linear models, covarying age, gender, and education. Analyses were conducted with and without correction for multiple comparisons and for partial volume effects.
RESULTS: Volume-adjusted HM was decreased in high-amyloid MCI but close to normal in low-amyloid MCI and in high-amyloid CN. Both MCI groups had hippocampal atrophy, although less severe in low-amyloid MCI. High-amyloid CN and high-amyloid MCI had cortical hypometabolism. DISCUSSION: HM is decreased when both cognitive impairment and amyloid are present.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Association cortex; FDG-PET; Hippocampus; Metabolism; Mild cognitive impairment

Mesh:

Substances:

Year:  2016        PMID: 27421609      PMCID: PMC5148703          DOI: 10.1016/j.jalz.2016.06.2357

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  42 in total

1.  Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Authors:  Gad A Marshall; Natacha Lorius; Joseph J Locascio; Bradley T Hyman; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

Review 3.  Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

Authors:  Karl Herholz
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

Review 4.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease.

Authors:  Josephine Barnes; Jonathan W Bartlett; Laura A van de Pol; Clement T Loy; Rachael I Scahill; Chris Frost; Paul Thompson; Nick C Fox
Journal:  Neurobiol Aging       Date:  2008-03-17       Impact factor: 4.673

5.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

6.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

7.  Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.

Authors:  Takashi Kawachi; Kazunari Ishii; Setsu Sakamoto; Masahiro Sasaki; Tetsuya Mori; Fumio Yamashita; Hiroshi Matsuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-21       Impact factor: 9.236

8.  Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.

Authors:  Byoung Seok Ye; Sang Won Seo; Chi Hun Kim; Seun Jeon; Geon Ha Kim; Young Noh; Hanna Cho; Cindy W Yoon; Hee Jin Kim; Eun Young Jang; Jeongmin Lee; Jung-Hyun Kim; Juhee Chin; Jong Min Lee; Jeong-Hun Kim; Joon-kyung Seong; Chang-Hun Kim; Yearn Seong Choe; Kyung Han Lee; Duk L Na
Journal:  Neurobiol Aging       Date:  2013-09-27       Impact factor: 4.673

9.  Clinical and multimodal biomarker correlates of ADNI neuropathological findings.

Authors:  Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski
Journal:  Acta Neuropathol Commun       Date:  2013-10-09       Impact factor: 7.801

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  14 in total

1.  Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.

Authors:  Julien Dumurgier; Bernard J Hanseeuw; Frances B Hatling; Kelly A Judge; Aaron P Schultz; Jasmeer P Chhatwal; Deborah Blacker; Reisa A Sperling; Keith A Johnson; Bradley T Hyman; Teresa Gómez-Isla
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

2.  Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.

Authors:  Bernard J Hanseeuw; Rebecca A Betensky; Aaron P Schultz; Kathryn V Papp; Elizabeth C Mormino; Jorge Sepulcre; John S Bark; Danielle M Cosio; Molly LaPoint; Jasmeer P Chhatwal; Dorene M Rentz; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2017-04-06       Impact factor: 10.422

3.  Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.

Authors:  Matthew R Scott; Olivia L Hampton; Rachel F Buckley; Jasmeer P Chhatwal; Bernard J Hanseeuw; Heidi Il Jacobs; Michael J Properzi; Justin S Sanchez; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2020-06-05       Impact factor: 6.556

4.  Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden.

Authors:  Patrizia Vannini; Bernard Hanseeuw; Catherine E Munro; Rebecca E Amariglio; Gad A Marshall; Dorene M Rentz; Alvaro Pascual-Leone; Keith A Johnson; Reisa A Sperling
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

5.  Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.

Authors:  Danielle V Mayblyum; J Alex Becker; Heidi I L Jacobs; Rachel F Buckley; Aaron P Schultz; Jorge Sepulcre; Justin S Sanchez; Zoe B Rubinstein; Samantha R Katz; Kirsten A Moody; Patrizia Vannini; Kathryn V Papp; Dorene M Rentz; Julie C Price; Reisa A Sperling; Keith A Johnson; Bernard J Hanseeuw
Journal:  Neurology       Date:  2021-05-05       Impact factor: 9.910

6.  EEG-fMRI Signal Coupling Is Modulated in Subjects With Mild Cognitive Impairment and Amyloid Deposition.

Authors:  Lars Michels; Florian Riese; Rafael Meyer; Andrea M Kälin; Sandra E Leh; Paul G Unschuld; Roger Luechinger; Christoph Hock; Ruth O'Gorman; Spyros Kollias; Anton Gietl
Journal:  Front Aging Neurosci       Date:  2021-04-23       Impact factor: 5.750

7.  Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults.

Authors:  Theresa M Harrison; Richard Du; Giuliana Klencklen; Suzanne L Baker; William J Jagust
Journal:  Alzheimers Dement       Date:  2020-12-15       Impact factor: 21.566

8.  Altered amygdala and hippocampus effective connectivity in mild cognitive impairment patients with depression: a resting-state functional MR imaging study with granger causality analysis.

Authors:  Li Juan Zheng; Gui Fen Yang; Xin Yuan Zhang; Yun Fei Wang; Ya Liu; Gang Zheng; Guang Ming Lu; Long Jiang Zhang; Ying Han
Journal:  Oncotarget       Date:  2017-04-11

9.  Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients.

Authors:  Clémence Tomadesso; Vincent de La Sayette; Robin de Flores; Pierrick Bourgeat; Victor L Villemagne; Stéphanie Egret; Francis Eustache; Gaël Chételat
Journal:  Alzheimers Dement (Amst)       Date:  2018-03-17

10.  Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults.

Authors:  Jennifer R Gatchel; Jennifer S Rabin; Rachel F Buckley; Joseph J Locascio; Yakeel T Quiroz; Hyun-Sik Yang; Patrizia Vannini; Rebecca E Amariglio; Dorene M Rentz; Michael Properzi; Nancy J Donovan; Deborah Blacker; Keith A Johnson; Reisa A Sperling; Gad A Marshall
Journal:  JAMA Netw Open       Date:  2019-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.